Replies to post #205911 on Biotech Values

[dewophile]

So if I understand correctly you are saying the adjacent protein can alter the folding of the linker in some way say through steric inhibition and thereby make the linker itself antigenic without affecting the activity of the protein moieties on either end. That makes sense and explains how an identical linker might cause an immune reaction in one case and not in another. I'm not biting my fingernails on this point to be honest. Efficacy and to a lesser extent leukopenia are the greater concerns for me. the upside if the drug works though outweighs these risks for me

[biomaven0]

>>I'm not saying TRIL shareholders should be biting their fingernails on this point.

Antigenicity far down my list of potential concerns for TRIL. I'd guess neutralizing antibodies even if they developed (for which there is zero evidence) wouldn't prove insuperable - I would think you could just increase the dose some. That's the great thing about an on-target DLT - any loss in potency can be overcome by increased dosing.

Of course if you start combining with CTLA4 drugs or the like who knows what might happen.

The main concern here (as with all the CD47 drugs) is pretty much all efficacy - we still lack robust proof of that.